Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT06092775
NCT06092775Not yet recruitingNot Applicable

Prevalence of Subclinical Vertebral Fractures in Rheumatoid Arthritis and Ankylosing Spondylitis in Egyptian Patients and Its Relation to Some Clinical Data

Assiut University0 sites93 target enrollmentStarted: December 2023Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Not yet recruiting
Enrollment
93
Primary Endpoint
Comparison of prevalence of subclinical vertebral fractures in RA ,AS and control group
Study OverviewStudy DesignEligibility CriteriaOutcomesInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

Study of prevalence of subclinical vertebral fractures in Rheumatoid Arthritis and Ankylosing spondylitis

Detailed Description

Detection of the prevalence of subclinical vertebral fractures in Rheumatoid Arthritis and Ankylosing spondylitis Study the relation between vertebral fractures and some clinical data like demographics data, disease duration and disease severity

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Eligibility Criteria

Ages
25 Years to 45 Years (Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • •Patients fulfilling ACR/EULAR 2010 rheumatoid arthritis classification criteria.
  • •Patients diagnosed as ankylosing spondylitis according to ASAS criteria (2000). Age (18-50).

Exclusion Criteria

  • •Patient with other autoimmune Rheumatic disease other than RA and AS. Infections including hepatitis C or B, HIV, tuberculosis. RA and AS patients with known vertebral fractures. Malignancy, hypogonadism, thyroid problems, chronic kidney disease, Hypoparathyroidism, Type 1 DM.
  • •Pregnancy and breast-feeding.

Outcomes

Primary Outcomes

Comparison of prevalence of subclinical vertebral fractures in RA ,AS and control group

Time Frame: Baseline

Detection of prevalence of subclinical vertebral fractures in RA, AS and control group

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

BASMA ZARIEF NAGEH FAHMY

Resident doctor

Assiut University

Similar Trials

Recruiting
Not Applicable
Incidence and riskfactors of vertebral fractures among geriatric outpatients
NL-OMON34850Slotervaartziekenhuis303
Not yet recruiting
Not Applicable
Prevalence and riskfactors of vertebral fractures among geriatric patientslow peak bone mass with fractures of the spineosteoporosis with bonefractures10005959
NL-OMON31187Slotervaartziekenhuis300
Unknown
Phase 4
A comparison of incidences of vertebral fracture in Japanese patients with osteoporosis treated with Etidronate and alfacalcidol; a randomized, double-blind studyPrimary osteoporosis
JPRN-jRCT1080220091Dainippon Sumitomo Pharma Co., Ltd.
Not yet recruiting
Not Applicable
A Registry Study Assessing PRO, Dosing Patterns, and Safety of Vunakizumab in Patients With General Rheumatic Diseases.Ankylosing Spondylitis (AS)Psoriatic Arthritis (PsA)Nr-axSpAPolymyalgia Rheumatica (PMR)Takayasu Arteritis (TAK)Giant Cell Arteritis (GCA)Enthesitis-related ArthritisBehcet's Disease
NCT06766552Second Affiliated Hospital, School of Medicine, Zhejiang University10,000
Recruiting
Not Applicable
ew (vertebral) fracture incidence in a patient population with a previuos fracturefracture and broken boneosteoporosis and decreased bone mineral densityrisk factors10017322
NL-OMON32423Academisch Ziekenhuis Maastricht492